Cargando…

Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer

PURPOSES: To evaluate the plan quality and robustness of both dose and dose rate of proton pencil beam scanning (PBS) transmission FLASH delivery in lung cancer treatment. METHODS AND MATERIALS: An in-house FLASH planning platform was used to optimize 10 lung cancer patients previously consecutively...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Shouyi, Lin, Haibo, Huang, Sheng, Shi, Chengyu, Xiong, Weijun, Zhai, Huifang, Hu, Lei, Yu, Gang, Press, Robert H., Hasan, Shaakir, Chhabra, Arpit M., Choi, J. Isabelle, Simone, Charles B., Kang, Minglei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9435957/
https://www.ncbi.nlm.nih.gov/pubmed/36059710
http://dx.doi.org/10.3389/fonc.2022.970602
_version_ 1784781262753366016
author Wei, Shouyi
Lin, Haibo
Huang, Sheng
Shi, Chengyu
Xiong, Weijun
Zhai, Huifang
Hu, Lei
Yu, Gang
Press, Robert H.
Hasan, Shaakir
Chhabra, Arpit M.
Choi, J. Isabelle
Simone, Charles B.
Kang, Minglei
author_facet Wei, Shouyi
Lin, Haibo
Huang, Sheng
Shi, Chengyu
Xiong, Weijun
Zhai, Huifang
Hu, Lei
Yu, Gang
Press, Robert H.
Hasan, Shaakir
Chhabra, Arpit M.
Choi, J. Isabelle
Simone, Charles B.
Kang, Minglei
author_sort Wei, Shouyi
collection PubMed
description PURPOSES: To evaluate the plan quality and robustness of both dose and dose rate of proton pencil beam scanning (PBS) transmission FLASH delivery in lung cancer treatment. METHODS AND MATERIALS: An in-house FLASH planning platform was used to optimize 10 lung cancer patients previously consecutively treated with proton stereotactic body radiation therapy (SBRT) to receive 3 and 5 transmission beams (Trx-3fds and Trx-5fds, respectively) to 34 Gy in a single fraction. Perturbation scenarios (n=12) for setup and range uncertainties (5 mm and 3.5%) were introduced, and dose-volume histogram and dose-rate-volume histogram bands were generated. Conventional proton SBRT clinical plans were used as a reference. RTOG 0915 dose metrics and 40 Gy/s dose rate coverage (V(40Gy/s)) were used to assess the dose and dose rate robustness. RESULTS: Trx-5fds yields a comparable iCTV D(2%) of 105.3%, whereas Trx-3fds resulted in inferior D(2%) of 111.9% to the clinical SBRT plans with D(2%) of 105.6% (p<0.05). Both Trx-5fds and Trx-3fds plans had slightly worse dose metrics to organs at risk than SBRT plans. Trx-5fds achieved superior dosimetry robustness for iCTV, esophagus, and spinal cord doses than both Trx-3fds and conventional SBRT plans. There was no significant difference in dose rate robustness for V(40Gy/s) coverage between Trx-3fds and Trx-5fds. Dose rate distribution has similar distributions to the dose when perturbation exists. CONCLUSION: Transmission plans yield overall modestly inferior plan quality compared to the conventional proton SBRT plans but provide improved robustness and the potential for a toxicity-sparing FLASH effect. By using more beams (5- versus 3-field), both dose and dose rate robustness for transmission plans can be achieved.
format Online
Article
Text
id pubmed-9435957
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94359572022-09-02 Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer Wei, Shouyi Lin, Haibo Huang, Sheng Shi, Chengyu Xiong, Weijun Zhai, Huifang Hu, Lei Yu, Gang Press, Robert H. Hasan, Shaakir Chhabra, Arpit M. Choi, J. Isabelle Simone, Charles B. Kang, Minglei Front Oncol Oncology PURPOSES: To evaluate the plan quality and robustness of both dose and dose rate of proton pencil beam scanning (PBS) transmission FLASH delivery in lung cancer treatment. METHODS AND MATERIALS: An in-house FLASH planning platform was used to optimize 10 lung cancer patients previously consecutively treated with proton stereotactic body radiation therapy (SBRT) to receive 3 and 5 transmission beams (Trx-3fds and Trx-5fds, respectively) to 34 Gy in a single fraction. Perturbation scenarios (n=12) for setup and range uncertainties (5 mm and 3.5%) were introduced, and dose-volume histogram and dose-rate-volume histogram bands were generated. Conventional proton SBRT clinical plans were used as a reference. RTOG 0915 dose metrics and 40 Gy/s dose rate coverage (V(40Gy/s)) were used to assess the dose and dose rate robustness. RESULTS: Trx-5fds yields a comparable iCTV D(2%) of 105.3%, whereas Trx-3fds resulted in inferior D(2%) of 111.9% to the clinical SBRT plans with D(2%) of 105.6% (p<0.05). Both Trx-5fds and Trx-3fds plans had slightly worse dose metrics to organs at risk than SBRT plans. Trx-5fds achieved superior dosimetry robustness for iCTV, esophagus, and spinal cord doses than both Trx-3fds and conventional SBRT plans. There was no significant difference in dose rate robustness for V(40Gy/s) coverage between Trx-3fds and Trx-5fds. Dose rate distribution has similar distributions to the dose when perturbation exists. CONCLUSION: Transmission plans yield overall modestly inferior plan quality compared to the conventional proton SBRT plans but provide improved robustness and the potential for a toxicity-sparing FLASH effect. By using more beams (5- versus 3-field), both dose and dose rate robustness for transmission plans can be achieved. Frontiers Media S.A. 2022-08-15 /pmc/articles/PMC9435957/ /pubmed/36059710 http://dx.doi.org/10.3389/fonc.2022.970602 Text en Copyright © 2022 Wei, Lin, Huang, Shi, Xiong, Zhai, Hu, Yu, Press, Hasan, Chhabra, Choi, Simone and Kang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wei, Shouyi
Lin, Haibo
Huang, Sheng
Shi, Chengyu
Xiong, Weijun
Zhai, Huifang
Hu, Lei
Yu, Gang
Press, Robert H.
Hasan, Shaakir
Chhabra, Arpit M.
Choi, J. Isabelle
Simone, Charles B.
Kang, Minglei
Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer
title Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer
title_full Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer
title_fullStr Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer
title_full_unstemmed Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer
title_short Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer
title_sort dose rate and dose robustness for proton transmission flash-rt treatment in lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9435957/
https://www.ncbi.nlm.nih.gov/pubmed/36059710
http://dx.doi.org/10.3389/fonc.2022.970602
work_keys_str_mv AT weishouyi doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer
AT linhaibo doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer
AT huangsheng doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer
AT shichengyu doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer
AT xiongweijun doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer
AT zhaihuifang doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer
AT hulei doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer
AT yugang doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer
AT pressroberth doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer
AT hasanshaakir doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer
AT chhabraarpitm doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer
AT choijisabelle doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer
AT simonecharlesb doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer
AT kangminglei doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer